Assessing commercial opportunities for autologous and allogeneic cell-based products

Regenerative Medicine

Volumn 7, Issue 5, 2012, Pages 721-732

  Smith, Devyn M ^a  

^a PFIZER GLOBAL RESEARCH AND DEVELOPMENT   (United Kingdom)

Author keywords

allogeneic; autologous; business model; cardiovascular disease; commercialization; peripheral vascular disease

Indexed keywords

ADVERTIZING; CELL THERAPY; CLINICAL EFFECTIVENESS; COMPARATIVE EFFECTIVENESS; COST BENEFIT ANALYSIS; HEALTH CARE COST; HEALTH CARE INDUSTRY; HUMAN; INCOME; PERIPHERAL VASCULAR DISEASE; PRIORITY JOURNAL; PRODUCT DEVELOPMENT; PRODUCT SAFETY; REVIEW; SOCIAL MARKETING; SOCIAL MEDICINE; TREATMENT INDICATION;

CLINICAL TRIALS AS TOPIC; COMMERCE; HUMANS; MODELS, ECONOMIC; STEM CELL TRANSPLANTATION; TRANSPLANTATION, AUTOLOGOUS; TRANSPLANTATION, HOMOLOGOUS;

EID: 84866083976     PISSN: 17460751     EISSN: 1746076X     Source Type: Journal    
DOI: 10.2217/rme.12.40     Document Type: Review

References (26)

1. Smith D. Successful business models for cell-based therapies. In: THE World Stem Cell Report 2008. Siegal B (Ed.). Genetics Policy Institute, FL, USA, 158-162 (2008).
2. Mason C, Brindley DA, Culme-Seymour EJ, Davie NL. Cell therapy industry: Billion dollar global business with unlimited potential. Regen. Med. 6, 265-272 (2011).
3. Mason C, Manzotti E. Regenerative medicine cell therapies: Numbers of units manufactured and patients treated between 1988 and 2010. Regen. Med. 5, 307-313 (2010).
4. McKernan R, McNeish J, Smith D. Pharma's developing interest in stem cells. Cell Stem Cell 6, 517-520 (2010).
5. Smith D. Creating partnerships with large pharma? Getting ready for the big day. In: THE World Stem Cell Report 2009. Siegal B (Ed.). Genetics Policy Institute, FL, USA, 131-137 (2009).
6. Plagnol AD, Rowley E, Martin P, Livesey F. Industry perceptions of barriers to commercialization of regenerative medicine products in the UK. Regen. Med. 4, 549-559 (2009).
7. Caine B, Montgomery SA. Building a bridge to commercial success. Bioprocess Int. 9(Suppl. 1), 1-55 (2011).
8. Smith D. Commercialization challenges associated with induced pluripotent stem cell-based products. Regen. Med. 5, 593-604 (2009).
9. Mason C, Dunnill P. Assessing the value of autologous and allogeneic cells for regenerative medicine. Regen. Med. 4, 835-853 (2009).
10. Buckler RL. Opportunities in regenerative medicine - the global industry and market trends. Bioprocess Int. 9(Suppl. 1), 14-19 (2011).
11. Driscoll D. Addressing business models, reimbursement, and cost of goods. Bioprocess Int. 9(Suppl. 1), 46-49 (2011).
12. Farid SS. Process economics of industrial monoclonal antibody manufacture. J. Chromatogr. B Analyt. Technol. Biomed. Life Sci. 15, 8-18 (2007). (Pubitemid 46367764)
13. Strauer BE, Brehm M, Zeus T et al. Intracoronary human autologous stem cell transplantation for myocardial regeneration following myocardial infarction. Dtsch Med. Wschr. 126, 932-938 (2001). (Pubitemid 32844014)
14. Strauer BE, Steinhoff G. 10 years of intracoronary and intramyocardial bone marrow stem cell therapy of the heart: From the methodological origin to clinical practice. J. Am. Coll. Cardiol. 58, 1095-1104 (2011).
15. Menasche P. Cardiac cell therapy: Lessons from clinical trials. J. Mol. Cell. Cardiol. 50, 258-265 (2011).
16. Wen Y, Meng L, Ding Y, Ouyang J. Autologous transplantation of blood-derived stem/progenitor cells for ischaemic heart disease. Int. J. Clin. Pract. 65, 858-865 (2011).
17. Mozid AM, Arnous S, Sammut EC, Mathur A. Stem cell therapy for heart diseases. Br. Med. Bull. 98, 143-159 (2011).
18. Sachs T, Pomposelli F, Hamdan A et al. Trends in the national outcomes and costs for claudication and limb threatening ischemia: Angioplasty vs bypass graft patients. J. Vasc. Surg. 54, 1021-1031 (2011).
19. Gresele P, Busti C, Fierro T. Critical limb ischemia. Intern. Emerg. Med. 1, 129-134 (2011).
20. Schanzer A, Conte MS. Critical limb ischemia. Curr. Treat. Options Cardiovasc. Med. 12, 214-229 (2010).
21. Murphy MP, Wang H, Patel AN et al. Allogeneic endometrial regenerative cells: An 'off the shelf solution' for critical limb ischemia. J. Transl. Med. 6, 45 (2008).
22. Tateishi-Yuyama E, Matsubara H, Murohara T et al.; Therapeutic Angiogenesis using Cell Transplantation (TACT) Study Investigators. Therapeutic angiogenesis for patients with limb ischaemia by autologous transplantation of bone-marrow cells: A pilot study and a randomized controlled trial. Lancet 360, 427-435 (2002).
23. Lawall H, Bramlage P, Amann B. Stem cell and progenitor cell therapy in peripheral artery disease - A critical appraisal. Thromb. Haemost. 103, 696-709 (2010).
24. Lawall H, Bramlage P, Amann B, Mahlow K. Treatment of peripheral arterial disease using stem and progenitor cell therapy. J. Vasc. Surg. 53, 445-453 (2011).
25. Moazzami K, Majdzadeh R, Nedjat S. Local intramuscular transplantation of autologous mononuclear cells for critical lower limb ischaemia. Cochrane Database Syst. Rev. (12), CD008347 (2011).
26. Mahoney E, Wang K, Keo HH, Duval S et al. Vascular hospitalization rates and costs in patients with peripheral artery disease in the United States. Circ. Cardiovasc. Qual. Outcomes 3, 642-651 (2010).